Frequency Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$180.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Frequency Therapeutics's estimated annual revenue is currently $24M per year.(i)
  • Frequency Therapeutics received $42.0M in venture funding in January 2019.
  • Frequency Therapeutics's estimated revenue per employee is $240,200
  • Frequency Therapeutics's total funding is $180.3M.
  • Frequency Therapeutics's current valuation is $177.9M. (January 2022}

Employee Data

  • Frequency Therapeutics has 100 Employees.(i)
  • Frequency Therapeutics grew their employee count by -9% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.

keywords:N/A

$180.3M

Total Funding

100

Number of Employees

$24M

Revenue (est)

-9%

Employee Growth %

$177.9M

Valuation

N/A

Accelerator

Frequency Therapeutics News

2019-01-07 - Frequency Therapeutics Completes $42M Series B Financing

Frequency Therapeutics, a Woburn, Mass.-based clinical-stage biotechnology company creating a new class of drugs based on small molecule stimulation of dormant stem cells within the body which we refer to as Progenitor Cell Activation (PCA), closed a $42m Series B financing. The round, which br ...

2019-01-08 - Frequency Therapeutics secures $42m from Taiwania Capital, Axil, others

Premium US-based Frequency Therapeutics, a clinical-stage biotechnology company creating small molecule drugs, has completed raising $42 million in its Series B funding round led by Taiwania Capital Management and Axil Capital. Continue reading this story with a subscription to DealStreetAsia. ...

2019-07-24 - Frequency Therapeutics Closes $62M Series C Financing

Frequency Therapeutics, a Woburn, Mass.-based clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, closed a $62.0m Series C financing. The round was led by Perceptive Advisors and a syn ...

09/03/2019 - Frequency Therapeutics registers $100m IPO

Woburn, Mass.-based Frequency Therapeutics did not disclose the number of shares it seeks to sell or the price range of the offered units.

09/08/2019 - Frequency Plans IPO for Hearing Loss Drug & More ...

Hearing loss affects millions of Americans but to date, there are no FDA-approved medicines to treat them. Frequency Therapeutics is ...

09/03/2019 - Frequency Therapeutics Names Dana Hilt Chief Medical Officer

Frequency Therapeutics has appointed Dana Hilt to serve as its chief medical officer, the same position he held at Lysosomal Therapeutics.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.2M1013%N/A
#2
$15.2M105N/AN/A
#3
$25.6M1079%N/A
#4
$15.3M1097%N/A
#5
$31.6M1093%N/A

Frequency Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-04-12$32.0MACoBro VenturesArticle
2019-01-08$42.0MBTaiwania Capital ManagementArticle